within Pharmacolibrary.Drugs.ATC.B;

model B01AE05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.060000000000000005,
    adminDuration  = 600,
    adminMass      = 0.036,
    adminCount     = 1,
    Vd             = 0.018,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011166666666666667,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Ximelagatran is an oral direct thrombin inhibitor anticoagulant, formerly used for prevention of stroke and venous thromboembolism, as well as for the treatment of deep vein thrombosis. It was withdrawn from the market due to hepatotoxicity concerns and thus is not approved or used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from healthy adult volunteers (both sexes) under fasting conditions after oral administration.</p><h4>References</h4><ol><li><p>Gustafsson, D, &amp; Elg, M (2003). The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. <i>Thrombosis research</i> 109 Suppl 1 S9–S15. DOI:<a href=&quot;https://doi.org/10.1016/s0049-3848(03)00249-4&quot;>10.1016/s0049-3848(03)00249-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12818629/&quot;>https://pubmed.ncbi.nlm.nih.gov/12818629</a></p></li><li><p>Francis, CW (2004). Ximelagatran: a new oral anticoagulant. <i>Best practice &amp; research. Clinical haematology</i> 17(1) 139–152. DOI:<a href=&quot;https://doi.org/10.1016/j.beha.2004.03.005&quot;>10.1016/j.beha.2004.03.005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15171963/&quot;>https://pubmed.ncbi.nlm.nih.gov/15171963</a></p></li><li><p>Dorani, H, et al., &amp; Eriksson, UG (2007). Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran co-administered with different classes of antibiotics in healthy volunteers. <i>European journal of clinical pharmacology</i> 63(6) 571–581. DOI:<a href=&quot;https://doi.org/10.1007/s00228-007-0292-6&quot;>10.1007/s00228-007-0292-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17387462/&quot;>https://pubmed.ncbi.nlm.nih.gov/17387462</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AE05;
